Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?
- PMID: 17768067
- DOI: 10.1016/j.semcancer.2007.07.005
Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?
Abstract
There is strong evidence to support a role for non-classical MHC class I (class Ib) molecules, most notably HLA-E and HLA-G in tumour immune escape. In this article, we summarize the current knowledge on their expression, regulation and functional relevance in various malignancies, particularly brain tumours. Special emphasis is devoted to the phenomenon that these tolerogenic molecules are expressed by non-transformed cells that are found in close neighborhood to tumour cells representing either parenchymal cells or immune cells attracted to the tumour microenvironment. Here they may act as "natural" or "inducible" suppressors of anti-tumoural immune responses. We thus speculate about the role of HLA-G expressing T cells, a novel population of natural regulatory cells that was identified recently. It is suggested that various cell types within a tumour cooperate in order to inhibit anti-tumour immunity-and that immunetolerogenic HLA-G may play a major role in this context.
Similar articles
-
Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity.Brain. 2005 Nov;128(Pt 11):2689-704. doi: 10.1093/brain/awh609. Epub 2005 Aug 25. Brain. 2005. PMID: 16123145
-
HLA-G in B-chronic lymphocytic leukaemia: clinical relevance and functional implications.Semin Cancer Biol. 2007 Dec;17(6):430-5. doi: 10.1016/j.semcancer.2007.06.011. Epub 2007 Jun 28. Semin Cancer Biol. 2007. PMID: 17683947 Review.
-
HLA-G and its KIR ligands in cancer--another enigma yet to be solved?J Pathol. 2002 Mar;196(3):252-3. doi: 10.1002/path.1057. J Pathol. 2002. PMID: 11857486 Review.
-
Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer.J Pathol. 2002 Mar;196(3):266-74. doi: 10.1002/path.1039. J Pathol. 2002. PMID: 11857488
-
Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses.Semin Cancer Biol. 2007 Dec;17(6):413-21. doi: 10.1016/j.semcancer.2007.07.003. Epub 2007 Jul 17. Semin Cancer Biol. 2007. PMID: 17881247 Review.
Cited by
-
DNA Vaccines-How Far From Clinical Use?Int J Mol Sci. 2018 Nov 15;19(11):3605. doi: 10.3390/ijms19113605. Int J Mol Sci. 2018. PMID: 30445702 Free PMC article. Review.
-
Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.Front Immunol. 2017 Nov 13;8:1544. doi: 10.3389/fimmu.2017.01544. eCollection 2017. Front Immunol. 2017. PMID: 29181007 Free PMC article. Review.
-
The Primate EAE Model Points at EBV-Infected B Cells as a Preferential Therapy Target in Multiple Sclerosis.Front Immunol. 2013 Jun 13;4:145. doi: 10.3389/fimmu.2013.00145. eCollection 2013. Front Immunol. 2013. PMID: 23781220 Free PMC article.
-
Differences in Extracellular Vesicle Protein Cargo Are Dependent on Head and Neck Squamous Cell Carcinoma Cell of Origin and Human Papillomavirus Status.Cancers (Basel). 2021 Jul 23;13(15):3714. doi: 10.3390/cancers13153714. Cancers (Basel). 2021. PMID: 34359613 Free PMC article.
-
Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands.Tissue Antigens. 2008 Oct;72(4):321-34. doi: 10.1111/j.1399-0039.2008.01106.x. Epub 2008 Aug 12. Tissue Antigens. 2008. PMID: 18700879 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials